Ketamine shows genuine promise for easing opioid withdrawal symptoms, though it is not yet an approved treatment for this purpose. Early clinical evidence suggests that low-dose ketamine infusions can reduce or even eliminate the classic withdrawal symptoms, including pain, cravings, restlessness, nausea, and anxiety, when administered alongside standard medications during detox. The research is still limited to small studies and case reports, but the results have been encouraging enough that some hospitals already use it in practice.
How Ketamine Works During Withdrawal
Opioid withdrawal happens partly because the brain’s pain-signaling system rebounds after losing the drugs it adapted to. One key player in that rebound is the NMDA receptor, a protein on nerve cells involved in pain processing, learning, and tolerance. When you use opioids repeatedly, NMDA receptors ramp up their activity to compensate, contributing to both tolerance (needing higher doses) and the intense pain sensitivity that hits during withdrawal.
Ketamine blocks NMDA receptors. By doing so at low, carefully controlled doses, it appears to interrupt that rebound cycle. It dampens the heightened pain signaling, reduces the nervous system’s overreaction, and may even help “reset” some of the tolerance that built up during opioid use. This is different from how standard withdrawal medications work: buprenorphine and methadone act on opioid receptors themselves, while ketamine targets a separate pathway that feeds into withdrawal distress.
What the Clinical Evidence Shows
No large randomized controlled trials have been completed yet, but the smaller studies and case series that exist paint a consistent picture. In a five-day hospitalization protocol published in Regional Anesthesia & Pain Medicine, patients receiving low-dose ketamine infusions (averaging about 0.31 mg/kg per day) while tapering off opioids tolerated the process well and did not develop significant withdrawal symptoms. In a detailed case report published in BMC Psychiatry, a patient scored 0 out of 11 on a standard opioid withdrawal scale during the first two weeks of opioid reduction under ketamine treatment. She reported no pain, no cravings, no nausea, no restlessness, and no worsening of her pre-existing depression.
These findings are small-scale, but the pattern is notable: across multiple clinical settings, ketamine-assisted tapering appears to blunt the withdrawal experience significantly. A 2025 scoping review in Frontiers in Psychiatry compiled the existing evidence and found that ketamine was used successfully in several different withdrawal contexts, from rapid detox protocols to more gradual outpatient tapers.
Ketamine vs. Standard Withdrawal Treatments
A randomized, double-blind trial compared ketamine to buprenorphine as add-on treatments for people with both opioid use disorder and major depression. Ketamine produced a rapid, substantial drop in anxiety and cravings within hours of administration. Buprenorphine worked more gradually, with improvements building over several days. The interesting finding: by day seven, both groups had improved to roughly the same degree. The differences in anxiety reduction and craving intensity were no longer statistically significant.
This suggests ketamine is not necessarily superior to established medications over the course of a week, but it may offer a faster initial response. That speed matters. The first 24 to 72 hours of withdrawal are often when people relapse or abandon treatment. A medication that provides rapid relief during that critical window could help more people make it through to the other side.
Where Ketamine Fits in Current Treatment
One of the most practical applications right now involves a specific problem called buprenorphine-precipitated withdrawal. Buprenorphine is a first-line medication for opioid use disorder, but starting it can be tricky, especially for people using fentanyl. If buprenorphine is given too soon, it can actually trigger sudden, severe withdrawal. This complication discourages some patients and providers from initiating treatment at all.
Ketamine is being used in some emergency departments and clinics to prevent or treat this precipitated withdrawal, allowing patients to transition onto buprenorphine more safely and comfortably. Highland Hospital in Oakland, California, uses ketamine routinely for this purpose in its emergency department, and the American Society of Addiction Medicine has hosted educational sessions specifically on using ketamine to facilitate the fentanyl-to-buprenorphine transition. Clinical protocols in these settings typically involve IV ketamine at doses between 0.3 and 1 mg/kg, infused over 15 minutes to an hour.
Ketamine Is Not FDA-Approved for This Use
Ketamine is FDA-approved only as an anesthetic. It is not approved for treating any psychiatric disorder, opioid use disorder, or withdrawal. Every use for withdrawal management is considered off-label. This does not mean it is illegal or inherently dangerous in a medical setting (doctors prescribe medications off-label routinely), but it does mean no regulatory body has formally evaluated the evidence and confirmed it works for this specific purpose.
Ketamine is also a Schedule III controlled substance with its own potential for misuse. The FDA has issued warnings about compounded ketamine products, particularly those prescribed through telehealth platforms for at-home use, noting that safety and quality have not been evaluated for these formulations. The clinical use described in withdrawal studies involves carefully monitored IV infusions in hospital or clinic settings, which is a very different situation from unsupervised use.
Side Effects and Safety Considerations
At the low doses used for withdrawal management (typically 0.15 to 0.5 mg/kg), ketamine is generally well tolerated. The five-day infusion study reported no significant adverse effects. However, ketamine can cause dissociation (a feeling of detachment from your body or surroundings), dizziness, nausea, and increases in blood pressure and heart rate. At higher doses, these effects become more pronounced.
In the trial comparing ketamine to buprenorphine, two patients developed symptoms of mania after receiving ketamine and were removed from the study. This is uncommon but highlights why psychiatric monitoring matters during treatment. People with a history of psychosis or poorly controlled blood pressure may not be good candidates.
The question of whether ketamine itself could become a substance of misuse for someone already struggling with addiction is reasonable, but the clinical protocols involve short-term, supervised administration rather than ongoing prescriptions. The doses used are well below the anesthetic threshold and far below recreational levels.
What We Still Don’t Know
The biggest gap in the evidence is long-term outcomes. The existing studies document what happens during withdrawal and in the days immediately following, but there is very little data on whether ketamine-assisted detox leads to better sobriety rates months or years later. Withdrawal management alone, regardless of the method, has high relapse rates unless paired with ongoing medication and support. Whether ketamine’s rapid relief during the acute phase translates into better long-term engagement with treatment is an open question.
The studies to date also involve small numbers of patients, and most lack control groups. Larger randomized trials are needed before ketamine could move from a promising off-label tool to a standard part of withdrawal treatment. For now, it occupies a middle ground: not yet validated by the kind of evidence regulators require, but already being adopted by clinicians who see its value in real-world practice, particularly for the difficult fentanyl-to-buprenorphine transition that has become one of addiction medicine’s most pressing challenges.